CTOs on the Move

CEL-SCI

www.cel-sci.com

 
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body`s natural defense system.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.cel-sci.com
  • 8229 Boone Boulevard Suite 802
    Vienna, VA USA 22182
  • Phone: 703.506.9460

Executives

Name Title Contact Details

Funding

CEL-SCI raised $10M on 06/30/2020
CEL-SCI raised $31.7M on 06/11/2021

Similar Companies

Numira

Numira is a specialty preclinical CRO that combines innovative technologies and expertise to provide unique solutions to a wide variety of preclinical drug discovery efforts.   We support leading pharmaceutical, biotech, and medical device companies in the areas of discovery research and efficacy evaluation, offering services in the following areas - High-Resolution MicroCT Imaging, Image Analysis (microCT, MRI, ECG, histology data), Specialized Histology (GLP or non-GLP), 3D Oncology Cell Screening.   Utilizing our patented imaging reagents and powerful 3D visualization and analytic tools, we provide images, metrics, and analyses that will allow definitive answers much more rapidly and accurately than ever before, saving your team valuable time and resources.

Zymergen

Founded in 2013 and based in the San Francisco Bay Area, Zymergen integrates automation, machine learning, and genomics to rapidly accelerate the pace of scientific advancement. We treat the genome as a search space, leveraging machine learning to make discoveries far beyond the bounds of human intuition. In doing so, we deliver economic value, material diversity and performance capabilities not previously possible.

Epicentre Technologies Corp

Epicentre Technologies Corp is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boston Biomedical Research Institute

The Boston Biomedical Research Institute (BBRI) is dedicated to basic biomedical research to promote the understanding, treatment and prevention of specific human diseases. The areas of investigation concern the structure and function of muscle proteins,

Valitor

Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Our technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. We currently have development pipelines in the fields of dermatology, ophthalmology, orthopedics, and stem cell therapy that highlight the capabilities of our novel drug products.